Article
Open Access
Volume 5 · Issue 3 · 2025
pp. 112–116
Comparative Evaluation of Fibrinolytic System Parameters in Newly Diagnosed Polycythemia Vera and Essential Thrombocythemia Patients
Buğra Öztosun1 
, Alev Kural2 , Ümit Barbaros Üre3 , Özlem Harmankaya4
, Alev Kural2 , Ümit Barbaros Üre3 , Özlem Harmankaya4
1
Department of Medical Oncology, Mersin City Training and Research Hospital, Mersin, Türkiye
2
Department of Biochemistry, Bakırköy Dr. Sadi Konuk Training and Research Hospital, İstanbul, Türkiye
3
Department of Hematology, Koç University School of Medicine, İstanbul, Türkiye
4
Department of Nephrology, Biruni University School of Medicine, İstanbul, Türkiye
Abstract
Objectives: Thrombotic complications are major determinants of morbidity and mortality in polycythemia vera (PV) and essential thrombocythemia (ET), yet the role of fibrinolytic dysfunction remains unclear. This study evaluated tissue plasminogen activator (tPA), plasminogen activator inhibitor-1 (PAI-1), and thrombin-activatable fibrinolysis inhibitor (TAFI) in newly diagnosed patients with PV and ET.
Methods: In this prospective, single-center, comparative cross-sectional study, 46 newly diagnosed patients with myelo-proliferative neoplasms, including 17 with PV and 29 with ET, and 36 healthy controls were included. Serum tPA, PAI-1, and TAFI levels were measured by enzyme-linked immunosorbent assay and compared between groups.
Results: Among the fibrinolytic parameters, tPA levels differed significantly between groups (p=0.015). Both patients with PV and those with ET had lower tPA levels than healthy controls. No significant differences were observed in PAI-1 or TAFI levels.
Conclusion: Newly diagnosed patients with PV and ET showed reduced tPA levels, suggesting impaired fibrinolytic activation. These findings support a possible contribution of hypofibrinolysis to the prothrombotic tendency of myelo-proliferative neoplasms.
Methods: In this prospective, single-center, comparative cross-sectional study, 46 newly diagnosed patients with myelo-proliferative neoplasms, including 17 with PV and 29 with ET, and 36 healthy controls were included. Serum tPA, PAI-1, and TAFI levels were measured by enzyme-linked immunosorbent assay and compared between groups.
Results: Among the fibrinolytic parameters, tPA levels differed significantly between groups (p=0.015). Both patients with PV and those with ET had lower tPA levels than healthy controls. No significant differences were observed in PAI-1 or TAFI levels.
Conclusion: Newly diagnosed patients with PV and ET showed reduced tPA levels, suggesting impaired fibrinolytic activation. These findings support a possible contribution of hypofibrinolysis to the prothrombotic tendency of myelo-proliferative neoplasms.
Keywords: Essential thrombocythemia, fibrinolytic system, polycythemia vera
Current Issue Vol 5 · Iss 3
